THE ROLE OF THE SYMPATHOADRENAL SYSTEM IN CARDIAC REMODELING AFTER MYOCARDIAL REVASCULARIZATION

Main Article Content

Kholmirzayev S.A.
To‘xtamirzayev M.H.

Abstract

This review article analyzes the role of the sympathoadrenal system in cardiac remodeling after myocardial revascularization in patients with ischemic heart disease. Restoration of coronary blood flow by percutaneous coronary intervention or coronary artery bypass grafting may improve myocardial perfusion, reduce ischemic burden and create conditions for reverse remodeling. However, post-revascularization recovery of left ventricular ejection fraction, ventricular geometry, myocardial fibrosis and hypertrophy depends not only on the anatomical success of revascularization, but also on neurohumoral regulation, autonomic balance, oxidative stress and structural myocardial changes. Persistent sympathoadrenal activation is associated with increased catecholamine secretion, elevated myocardial oxygen demand, calcium overload, β-adrenergic receptor desensitization, fibroblast activation, collagen deposition and pathological hypertrophy. Therefore, the integrated assessment of ejection fraction, left ventricular geometry, fibrosis, hypertrophy and sympathoadrenal activity may improve the understanding of residual cardiovascular risk after revascularization.

Article Details

Section

Articles

References

1.Vrints C., Andreotti F., Koskinas K.C., et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. European Heart Journal. 2024;45:3415–3537. doi:10.1093/eurheartj/ehae177.

2.McDonagh T.A., Metra M., Adamo M., et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2023;44:3627–3639. doi:10.1093/eurheartj/ehad195.

3.McEvoy J.W., McCarthy C.P., Bruno R.M., et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. European Heart Journal. 2024;45:3912–4018. doi:10.1093/eurheartj/ehae178.

4.Perera D., Clayton T., O’Kane P.D., et al. Percutaneous revascularization for ischemic left ventricular dysfunction. New England Journal of Medicine. 2022;387:1351–1360. doi:10.1056/NEJMoa2206606.

5.Velazquez E.J., Lee K.L., Jones R.H., et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. New England Journal of Medicine. 2016;374:1511–1520. doi:10.1056/NEJMoa1602001.

6.Frantz S., Hundertmark M.J., Schulz-Menger J., Bengel F.M., Bauersachs J. Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies. European Heart Journal. 2022;43:2549–2561. doi:10.1093/eurheartj/ehac223.

7.Czubryt M.P., Hale T.M. Cardiac fibrosis: pathobiology and therapeutic targets. Cell Signalling. 2021;85:110066. doi:10.1016/j.cellsig.2021.110066.

8.Chen H.S., van Roon L., Schoones J.W., et al. Cardiac sympathetic hyperinnervation after myocardial infarction: a systematic review and qualitative analysis. Annals of Medicine. 2023;55:2278873. doi:10.1080/07853890.2023.2278873.

9.Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. European Heart Journal. 1996;17:354–381.

10.Heidenreich P.A., Bozkurt B., Aguilar D., et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145–e1032. doi:10.1161/CIR.0000000000001063.